Bristol-Myers Squibb Company (BMY)
| Market Cap | 106.16B |
| Revenue (ttm) | 48.03B |
| Net Income (ttm) | 6.04B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.97 |
| PE Ratio | 17.56 |
| Forward PE | 8.37 |
| Dividend | $2.48 (4.77%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 15,667,391 |
| Open | 51.99 |
| Previous Close | 51.95 |
| Day's Range | 51.69 - 52.51 |
| 52-Week Range | 42.52 - 63.33 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 55.58 (+6.58%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $55.58, which is an increase of 6.58% from the latest price.
News
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL...
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.
Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed.
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities
Bristol Myers Squibb & Co. (NYSE: BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
LOS ANGELES--(BUSINESS WIRE)-- #biotech--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb.
Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease.
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, includ...
What Is Happening With BMY Stock?
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 bil...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio.
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever
Drug companies face fairly normal industry dynamics that can leave them unloved on Wall Street over short periods of time. Pfizer is facing a patent cliff and is making a big move to revamp its drug p...
2 Top Dividend Stocks to Buy and Hold
Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend?
Bristol Myers has struggled to generate growth in recent years. Its high debt load has come down but remains a burden for the business.
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project n...
Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference.
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma.
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.
Bristol Myers Squibb to Host Hematology-Focused Investor Event
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Host Hematology-Focused Investor Event.
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity. BMY's pipeline and recent acquisitions are unlikely to offset revenue...
Bristol Myers, Sanofi sued by Texas over Plavix
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for...
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
Bristol Myers Squibb trades at seven times earnings, with multiple growth drivers.